JUMPCAN(SH:600566)2022-10-23 16:00Financial Performance - The company's operating revenue for Q3 2022 was CNY 2,030,551,584.20, representing a year-on-year increase of 17.58%[4] - The net profit attributable to shareholders for Q3 2022 was CNY 576,544,411.43, up 37.89% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses for Q3 2022 was CNY 545,842,379.01, an increase of 39.74% year-on-year[5] - The basic earnings per share for Q3 2022 was CNY 0.649, reflecting a growth of 37.79% compared to the previous year[5] - The diluted earnings per share for Q3 2022 was CNY 0.639, which is a 37.12% increase year-on-year[5] - Total operating revenue for the first three quarters of 2022 reached ¥5,893,672,580.32, an increase of 8.93% compared to ¥5,409,065,275.26 in the same period of 2021[19] - Net profit for the first three quarters of 2022 was ¥1,593,329,185.71, representing a growth of 25.3% from ¥1,271,486,269.70 in 2021[20] - Earnings per share (EPS) for the first three quarters of 2022 was ¥1.792, compared to ¥1.432 in the same period last year, indicating a 25.2% increase[21] - The company reported a profit before tax of ¥1,857,540,300.56, which is an increase from ¥1,473,047,507.51 in the previous year, representing a growth of 26.1%[20] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to CNY 13,294,210,230.73, representing a 9.59% increase from the end of the previous year[5] - As of September 30, 2022, the total assets of Hubei Jichuan Pharmaceutical Co., Ltd. amounted to CNY 13,294,210,230.73, an increase from CNY 12,131,036,777.90 at the end of 2021[14] - The company's current assets totaled CNY 9,449,791,698.22, up from CNY 8,122,784,414.33 in the previous year, indicating a growth of approximately 16.3%[14] - Total liabilities reached CNY 9,449,791,698.22, compared to CNY 8,122,784,414.33 in the previous year, indicating an increase of approximately 16.3%[15] - The total liabilities increased to ¥3,172,331,799.48 in Q3 2022 from ¥2,999,987,775.25 in Q3 2021, marking a rise of 5.76%[17] - The total equity attributable to shareholders reached ¥10,106,492,092.17, up from ¥9,116,878,404.95, reflecting an increase of 10.87% year-on-year[17] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 2,022,102,729.96, an increase of 26.76% year-on-year[5] - The cash inflow from operating activities for the first three quarters of 2022 was approximately CNY 7.34 billion, an increase of 11.9% compared to CNY 6.55 billion in the same period of 2021[22] - The net cash outflow from investing activities was approximately CNY -2.25 billion in 2022, compared to CNY -118.93 million in 2021, indicating a significant increase in investment expenditures[24] - The net cash outflow from financing activities was approximately CNY -508.37 million in 2022, compared to CNY -350.09 million in 2021, reflecting increased financial obligations[25] - The total cash and cash equivalents at the end of Q3 2022 stood at approximately CNY 3.08 billion, down from CNY 4.09 billion at the end of Q3 2021, indicating a decrease of 24.8%[25] - The cash inflow from sales of goods and services for the first three quarters of 2022 was approximately CNY 6.75 billion, up from CNY 6.21 billion in the same period of 2021, marking a growth of 8.7%[22] - The cash outflow for payments to employees in the first three quarters of 2022 was approximately CNY 646.32 million, a decrease from CNY 704.54 million in 2021, showing a reduction of 8.2%[24] - The cash inflow from investment activities totaled approximately CNY 3.13 billion in 2022, slightly down from CNY 3.19 billion in 2021, indicating a stable investment return[24] - The cash outflow for purchasing goods and services was approximately CNY 953.36 million in 2022, compared to CNY 719.22 million in 2021, reflecting an increase of 32.5%[22] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥252,530,629.98, compared to ¥220,467,726.46 in 2021, showing a growth of 14.55%[19] Company Outlook - The company attributed the growth in net profit to increased sales performance and effective cost control measures[9] - The company has not provided specific guidance or outlook for future performance in the available data[12]